Teva’s new chief executive reshapes company

28 November 2017 - Deborah Wilkes

Archived

Teva’s new president and chief executive officer Kare Schultz is restructuring the Israeli generics company around three geographic regions. Each region will manage the entire portfolio – including generic, specialty and OTC products – with “full end-to-end profit and loss accountability”.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: